Amedeo Smart

Free Medical Literature Service


 

Amedeo

Stem Cell Research

  Free Subscription

Articles published in
Leuk Lymphoma
    September 2022
  1. VILLALBA A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, et al
    Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
    Leuk Lymphoma. 2022 Sep 20:1-10. doi: 10.1080/10428194.2022.2123229.
    >> Share

  2. SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
    Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
    >> Share

  3. LU Y, Xiong M, Sun RJ, Zhang JP, et al
    Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-10. doi: 10.1080/10428194.2022.2118527.
    >> Share

  4. LU Y, Sun RJ, Zhang JP, Xu F, et al
    Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-8. doi: 10.1080/10428194.2022.2118531.
    >> Share

    August 2022
  5. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    >> Share

    July 2022
  6. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.
    >> Share

  7. ZAMA D, Mondardini MC, Petris MG, Amigoni A, et al
    Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2095628.
    >> Share

    June 2022
  8. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
    >> Share

  9. LIU Y, Qi L, Wang T, Zhou B, et al
    The clinical outcomes of mixed engraftment patients treated with haploidentical stem cells combined with umbilical cord blood transplantation.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086245.
    >> Share

  10. HO M, Moscvin M, Low SK, Evans B, et al
    Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2084729.
    >> Share

  11. LAHOUD OB, Landau H, Nguyen J, Devlin S, et al
    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Leuk Lymphoma. 2022 Jun 1:1-10. doi: 10.1080/10428194.2022.2062347.
    >> Share

    May 2022
  12. HOWELLS L, Chan WY, Sanchez E, Horder J, et al
    Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.
    Leuk Lymphoma. 2022 May 14:1-5. doi: 10.1080/10428194.2022.2074989.
    >> Share

  13. GERTZ MA, Warsame R, Muchtar E, Buadi F, et al
    Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 May 12:1-6. doi: 10.1080/10428194.2022.2074993.
    >> Share

    April 2022
  14. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    >> Share

  15. TAMAKI M, Nakasone H, Nakamura Y, Kawamura M, et al
    Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 7:1-9. doi: 10.1080/10428194.2022.2057486.
    >> Share

    March 2022
  16. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    >> Share

    February 2022
  17. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    >> Share

  18. KAMADA Y, Arima N, Hayashida M, Nakamura D, et al
    Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab.
    Leuk Lymphoma. 2022 Feb 27:1-7. doi: 10.1080/10428194.2022.2043300.
    >> Share

  19. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    >> Share

    January 2022
  20. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    >> Share

  21. IKEDA D, Tsushima T, Fukumoto A, Kuzume A, et al
    Rapid liver atrophy and refractory ascites due to hepatoportal sclerosis in a patient after haploidentical stem cell transplantation.
    Leuk Lymphoma. 2022 Jan 12:1-4. doi: 10.1080/10428194.2022.2027400.
    >> Share

    December 2021
  22. LU Y, Zhao YL, Xiong M, Sun RJ, et al
    Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.
    Leuk Lymphoma. 2021 Dec 16:1-9. doi: 10.1080/10428194.2021.2015588.
    >> Share

  23. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    >> Share

    November 2021
  24. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
    >> Share

  25. HOSOI H, Matsuyama Y, Murata S, Mushino T, et al
    Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 16:1-4. doi: 10.1080/10428194.2021.2005047.
    >> Share

  26. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
    >> Share

  27. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    >> Share

    October 2021
  28. ALHOMOUD M, Williams A, Magro C, Van Besien K, et al
    Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
    Leuk Lymphoma. 2021 Oct 20:1-5. doi: 10.1080/10428194.2021.1992625.
    >> Share

  29. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    >> Share

  30. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.
    >> Share

    September 2021
  31. PAVIGLIANITI A, Sestili S, Bianchessi A, Memoli M, et al
    Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984460.
    >> Share

  32. SAWALHA Y, Radivoyevitch T, Jia X, Tullio K, et al
    The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2021 Sep 15:1-9. doi: 10.1080/10428194.2021.1978085.
    >> Share

    August 2021
  33. PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
    Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
    Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
    >> Share

  34. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    >> Share

  35. DROZD-SOKOLOWSKA J, Waszczuk-Gajda A, Biecek P, Kobylinska K, et al
    Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy - a multicenter report by the Polish Myeloma Study Group.
    Leuk Lymphoma. 2021 Aug 16:1-9. doi: 10.1080/10428194.2021.1950712.
    >> Share

  36. RICHARDS H, Chavda SJ, Wilson W, Camilleri M, et al
    Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.
    Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961240.
    >> Share

    July 2021
  37. ENSSLE JC, Wolf S, von Metzler I, Weber S, et al
    High CD34 positive stem cell dosage improves thrombocyte recovery in obese myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2021 Jul 13:1-5. doi: 10.1080/10428194.2021.1950707.
    >> Share

    June 2021
  38. CAMILLERI M, McGrath T, Wilson W, Ings SJ, et al
    Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.
    Leuk Lymphoma. 2021 Jun 24:1-4. doi: 10.1080/10428194.2021.1941930.
    >> Share

  39. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    >> Share

  40. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.
    >> Share

  41. ZAMAGNI E, Dhanasiri S, Ghale A, Moore A, et al
    Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-b
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1924369.
    >> Share

    May 2021
  42. PASVOLSKY O, Shargian L, Rozovski U, Wolach O, et al
    Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation.
    Leuk Lymphoma. 2021 May 20:1-8. doi: 10.1080/10428194.2021.1929957.
    >> Share

  43. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.
    >> Share

  44. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    >> Share

    March 2021
  45. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    >> Share

  46. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    >> Share

  47. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021 Mar 25:1-8. doi: 10.1080/10428194.2021.1901090.
    >> Share

  48. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 21:1-3. doi: 10.1080/10428194.2021.1901097.
    >> Share

  49. SHEN Y, Qi J, Wang Y, Chen J, et al
    Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors.
    Leuk Lymphoma. 2021 Mar 18:1-4. doi: 10.1080/10428194.2021.1901095.
    >> Share

    February 2021
  50. MODI D, Albanyan O, Kim S, Deol A, et al
    Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2021 Feb 24:1-11. doi: 10.1080/10428194.2021.1891231.
    >> Share

    January 2021
  51. PRABAHRAN A, Koldej R, Chee L, Wong E, et al
    Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jan 31:1-13. doi: 10.1080/10428194.2021.1872072.
    >> Share

  52. JAIME-PEREZ JC, Hernandez-Coronado M, Picon-Galindo E, Salazar-Cavazos L, et al
    Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Leuk Lymphoma. 2021 Jan 24:1-10. doi: 10.1080/10428194.2021.1876870.
    >> Share

    December 2020
  53. PLATE M, van Besien K
    Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2020 Dec 27:1-3. doi: 10.1080/10428194.2020.1864357.
    >> Share

  54. MORIGI A, Casadei B, Argnani L, Stefoni V, et al
    Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-3. doi: 10.1080/10428194.2020.1855342.
    >> Share

    November 2020
  55. VOCKOVA P, Molinsky J, Klanova M, Karban J, et al
    CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.
    Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678.
    >> Share

  56. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    >> Share

  57. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    >> Share

  58. FU W, Huang A, Lu G, Ni X, et al
    Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
    Leuk Lymphoma. 2020 Nov 11:1-8. doi: 10.1080/10428194.2020.1845340.
    >> Share

  59. GAUT D, Mead M
    Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Leuk Lymphoma. 2020 Nov 2:1-24. doi: 10.1080/10428194.2020.1827251.
    >> Share

  60. ABBOUD R, Slade M, Abboud C, DiPersio JF, et al
    Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?
    Leuk Lymphoma. 2020 Nov 2:1-3. doi: 10.1080/10428194.2020.1839657.
    >> Share

  61. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.
    >> Share

    October 2020
  62. LIU W, Wu M, Xie Y, Zhang C, et al
    Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-7. doi: 10.1080/10428194.2020.1834092.
    >> Share

  63. SINGH V, Jang H, Kim S, Ayash L, et al
    G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.
    Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1827244.
    >> Share

  64. HEINICKE T, Labopin M, Polge E, Stelljes M, et al
    Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Leuk Lymphoma. 2020 Oct 11:1-11. doi: 10.1080/10428194.2020.1827248.
    >> Share

  65. MOUNTJOY L, Palmer J, Kunze KL, Khera N, et al
    Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?
    Leuk Lymphoma. 2020 Oct 4:1-3. doi: 10.1080/10428194.2020.1827249.
    >> Share

    September 2020
  66. LADHA A, Mannis G, Muffly L
    Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
    Leuk Lymphoma. 2020 Sep 29:1-7. doi: 10.1080/10428194.2020.1827247.
    >> Share

  67. TATARCZUCH M, Paul E, Gilberston M, Gregory GP, et al
    Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
    Leuk Lymphoma. 2020 Sep 27:1-6. doi: 10.1080/10428194.2020.1821007.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016